These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1979635)

  • 41. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.
    Schiess W; Welzel D; Gugler R
    Eur J Clin Pharmacol; 1984; 27(5):529-34. PubMed ID: 6151506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of bopindolol on the circadian blood pressure profile in essential hypertension.
    Favre L; Adamec R; Boxho G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S60-3. PubMed ID: 2439823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine.
    Török E; Borbás S; Lengyel M; Zorándi A
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S79-83. PubMed ID: 1376844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.
    van Brummelen P; Bühler FR; Amann FW; Bolli P
    Eur J Clin Pharmacol; 1982; 22(6):491-3. PubMed ID: 6127218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of chronic oral administration of a new beta-blocker, bopindolol, on serum lipoprotein concentrations and blood pressure of spontaneously hypertensive rats.
    Ishihara T; Chin WP; Yoshida Y; Sun HT; Mitomi A; Ishibashi T; Tamura K; Imai S
    Arch Int Pharmacodyn Ther; 1989; 302():145-57. PubMed ID: 2576891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bopindolol: Czechoslovak experience with a new beta blocker in the treatment of hypertension.
    Widimský J; Lefflerová K; Dvorák I; Fedelesová V; Lupínek Z; Mayer O; Pinterová E
    Am J Cardiol; 1991 Apr; 67(10):36B-42B. PubMed ID: 1673580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bopindolol in the treatment of moderate hypertension: a dose-response study.
    Moleur P; Peyrieux JC; Luciani J; David D; Boissel JP
    Fundam Clin Pharmacol; 1988; 2(5):431-40. PubMed ID: 2906897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bopindolol: long-term effects on blood pressure, renal function, plasma renin activity, and plasma aldosterone in mild-to-moderate essential hypertension.
    Shohat J; Modan M; Rosenfeld JB
    Fundam Clin Pharmacol; 1989; 3(1):53-8. PubMed ID: 2565862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Antihypertensive effect of bopindolol on stroke-prone spontaneously hypertensive rats (SHRSP)].
    Yamashita K; Shigematsu K; Maeda T; Ishida Y; Niwa M; Ozaki M
    Nihon Yakurigaku Zasshi; 1989 Jan; 93(1):7-15. PubMed ID: 2565861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma lipid fractions during bopindolol treatment in hypertensive patients.
    van Brummelen P; Bolli P; Koolen MI; Staehelin HB; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S42-4. PubMed ID: 2439818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of atenolol and bopindolol on circadian heart rate.
    Fitscha P; Meisner W; Tiso B
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S51-4. PubMed ID: 2439821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Beta-blockers in the treatment of hypertension in elderly patients].
    Lefflerová K; Widimský J; Lupínek Z
    Vnitr Lek; 1991 Feb; 37(2):128-34. PubMed ID: 1673577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bopindolol for the treatment of chronic stable angina pectoris--a clinical study of the relationship between dose and effect.
    Holmes D; Fryda-Kaurimsky Z; Krueger K
    Cardiology; 1990; 77(6):459-65. PubMed ID: 1981493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypotensive effect of bopindolol in pithed rats.
    Tanaka H; Takahashi S; Shigenobu K
    Gen Pharmacol; 1993 Mar; 24(2):373-5. PubMed ID: 8097742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
    Schiess W; Dorow P
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S30-3. PubMed ID: 2439815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients.
    Van Brummelen P; Bolli P; Koolen MI; Staehelin HB; Bühler FR
    Br J Clin Pharmacol; 1984 Jan; 17(1):86-8. PubMed ID: 6691892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial.
    Lüscher TF; Waeber B
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):305-9. PubMed ID: 7679166
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of bopindolol on left ventricular function during exercise in patients with coronary artery disease.
    Righetti A; Mérier G; Viquerat C; Ratib O; Rutishauser W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S39-41. PubMed ID: 2439817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.